Publication | Closed Access
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
1.2K
Citations
18
References
2024
Year
Semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease. (Funded by Novo Nordisk; FLOW ClinicalTrials.gov number, NCT03819153.).
| Year | Citations | |
|---|---|---|
Page 1
Page 1